Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147616 | 0.86 | NR1H4 (0.58) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL16148216 | 0.86 | MAPT (0.53) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL7302105 | 0.83 | SMN1; SMN2 (0.75) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL11761664 | 0.83 | KCNMA1 (0.73) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL13812835 | 0.82 | MAPT (0.70) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL11761696 | 0.82 | PLG (0.67) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL11337337 | 0.79 | MEN1 (0.76) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL330440 | 0.78 | HTT (0.56) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17515743 | 0.78 | MAPT (0.63) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL330019 | 0.77 | KCNMA1 (0.64) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | NORTH CAROLINA CENTRAL UNIV (US) | 2018-12-27 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | MEN1 1171/4885KMT2A 1812/4885MAPT 2394/4885 |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | GLS2, PC, GLS | MEN1 1171/4885KMT2A 1812/4885MAPT 2394/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | MEN1 1171/4885KMT2A 1812/4885MAPT 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.